Vericiguat study for kidney disease and heart failure patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have chronic kidney disease (GFR less than 90) and chronic heart failure (NYHA class II or higher)
- Your heart's pumping ability is reduced (LVEF 50% or less)
- Your potassium level in the past month was 4.8 or lower
- If you could become pregnant, you had a negative pregnancy test and will use birth control
- If you are on dialysis, your dialysis is effective (Kt/V >1.2 or URR >70%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
This trial tests whether starting the medication vericiguat soon after a heart attack can help people whose hearts are weakened (ejection fraction 45% or lower) and who developed heart failure. Vericiguat is an oral medicine that may reduce strain on the heart and improve outcomes when given early.
This trial tests whether adding vericiguat to your usual heart failure medicines helps reduce pressure in your lungs and improve symptoms. You will have a CardioMEMS sensor already implanted to monitor your heart, and the study will use its readings to guide your care.
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
This study tests if a new medicine (vicadrostat) works differently than an older one (spironolactone) in people with heart failure or heart disease and reduced kidney function. It aims to understand how they affect proteins in the blood and kidney blood flow.
This study tests whether a medication called vericiguat can improve chest pain caused by problems in the tiny blood vessels of the heart (not by large blockages). You may be a candidate if you have stable chest pain, are 40–75, and have had tests showing your heart's small vessels aren't working well.
Hear when a new Hemodialysis Complication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.